puromycin aminonucleoside has been researched along with Disease Exacerbation in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Fan, Y; Liu, Z; Shi, S; Wu, J; Zen, K; Zeng, C; Zhang, C; Zhong, Y | 1 |
Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M | 1 |
Bailey, S; Brown, T; Carraher, D; Homer, BL; Li, Y; Li, Z; Mathur, S; Nassirpour, R; O'Neil, SP; Percival, K; Warneke, J; Whiteley, LO | 1 |
Brinkkoetter, PT; Krofft, RD; Logar, CM; Pippin, JW; Shankland, SJ | 1 |
Magil, A | 1 |
Granados-Silvestre, MD; Hernández-Pando, R; Medina-Campos, ON; Pedraza-Chaverri, J | 1 |
Bastacky, S; Jackso, EK; Kost, CK; Rominski, BR; Tofovic, SP | 1 |
7 other study(ies) available for puromycin aminonucleoside and Disease Exacerbation
Article | Year |
---|---|
Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies.
Topics: Acute Kidney Injury; Animals; Apoptosis; Autophagy; Disease Models, Animal; Disease Progression; Female; Glomerulosclerosis, Focal Segmental; Humans; Male; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats, Wistar | 2014 |
Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Irbesartan; Kidney Glomerulus; Membrane Proteins; Nephrosis, Lipoid; Proteinuria; Puromycin Aminonucleoside; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors | 2014 |
Identification of Promising Urinary MicroRNA Biomarkers in Two Rat Models of Glomerular Injury.
Topics: Acute Kidney Injury; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Glomerulonephritis, Membranous; Heymann Nephritis Antigenic Complex; Immune Sera; Kidney Glomerulus; Laser Capture Microdissection; Male; Metabolomics; MicroRNAs; Microscopy, Electron, Transmission; Oxidative Stress; Podocytes; Puromycin Aminonucleoside; Rats, Sprague-Dawley; Sheep, Domestic | 2015 |
Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo.
Topics: Animals; Antibodies; Apoptosis; Autoantibodies; Cell Proliferation; Cells, Cultured; Darbepoetin alfa; Disease Models, Animal; Disease Progression; Erythropoietin; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Janus Kinase 2; Mice; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Proteins c-akt; Puromycin Aminonucleoside; Receptors, Erythropoietin; Signal Transduction; Transforming Growth Factor beta1; Ultraviolet Rays | 2007 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease Progression; Follow-Up Studies; Immunohistochemistry; Infusions, Intravenous; Kidney Glomerulus; Lipid Metabolism; Male; Nephrotic Syndrome; Probucol; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley | 1996 |
Effect of the in vivo catalase inhibition on aminonucleoside nephrosis.
Topics: Amitrole; Animals; Catalase; Disease Progression; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glutathione Peroxidase; Male; Nephrosis; Puromycin Aminonucleoside; Rats; Rats, Wistar; Reactive Oxygen Species | 1999 |
Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats.
Topics: Animals; Caffeine; Creatinine; Disease Progression; Drug Synergism; Kidney Cortex; Kidney Failure, Chronic; Kidney Function Tests; Male; Nephrosis; Phosphodiesterase Inhibitors; Proteinuria; Purinergic P1 Receptor Antagonists; Puromycin Aminonucleoside; Random Allocation; Rats; Rats, Sprague-Dawley; Renin | 2000 |